Comment
doi: 10.1093/annonc/mdl487.
Does low-molecular-weight heparin influence cancer-related mortality?
- PMID: 17322543
- DOI: 10.1093/annonc/mdl487
Item in Clipboard
Comment
Does low-molecular-weight heparin influence cancer-related mortality?
Ann Oncol.
2007 Mar.
Free article
No abstract available
Comment on
-
Does low-molecular-weight heparin influence cancer-related mortality?Ann Oncol. 2006 Oct;17(10):1604-6. doi: 10.1093/annonc/mdl092. Epub 2006 May 2. Ann Oncol. 2006. PMID: 16670203 No abstract available.
Similar articles
-
Prophylaxis and treatment of venous thromboembolism in patients with cancer.Intern Emerg Med. 2006;1(4):260-2. doi: 10.1007/BF02934757. Intern Emerg Med. 2006. PMID: 17217144 Review. No abstract available.
-
[Heparin and cancer].Ugeskr Laeger. 2006 Dec 11;168(50):4397-401. Ugeskr Laeger. 2006. PMID: 17217864 Review. Danish.
-
Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update.Intern Emerg Med. 2006;1(4):273-8. doi: 10.1007/BF02934760. Intern Emerg Med. 2006. PMID: 17217148 Review.
-
The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients.Curr Opin Pulm Med. 2003 Sep;9(5):351-5. doi: 10.1097/00063198-200309000-00002. Curr Opin Pulm Med. 2003. PMID: 12904702 Review.
-
Vitamin K antagonists in anticoagulant therapy of patients with cancer.Pol Arch Med Wewn. 2012;122(1-2):60-4. Pol Arch Med Wewn. 2012. PMID: 22353708 Review.
Cited by
-
Parenteral anticoagulation in ambulatory patients with cancer.Cochrane Database Syst Rev. 2017 Sep 11;9(9):CD006652. doi: 10.1002/14651858.CD006652.pub5. Cochrane Database Syst Rev. 2017. PMID: 28892556 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
